These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Effectiveness of an immunization campaign with group A and C meningococcal polysaccharide vaccine in controlling an outbreak of group C meningococcal disease]. Gong J; Li CY; Dong BQ; Huang JZ; Quan Y; Lu WZ; Luo CH; Mao WC; Liao HZ; Fang JS; Cui XL; Xie GL; Wu XH; Lan RW Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):552-5. PubMed ID: 19040035 [TBL] [Abstract][Full Text] [Related]
23. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420 [TBL] [Abstract][Full Text] [Related]
25. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Prasad K; Karlupia N Respir Med; 2007 Oct; 101(10):2037-43. PubMed ID: 17706408 [TBL] [Abstract][Full Text] [Related]
26. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Nakhla I; Frenck RW; Teleb NA; El Oun S; Sultan Y; Mansour H; Mahoney F Vaccine; 2005 May; 23(25):3288-93. PubMed ID: 15837234 [TBL] [Abstract][Full Text] [Related]
27. Diagnostic work with suspected cases of systemic meningococcal disease in the Norwegian serogroup B vaccine protection trials. Holten E; Bruun JN; Hellum KB; Maeland JA NIPH Ann; 1991 Dec; 14(2):103-6; discussion 121-3. PubMed ID: 1812423 [No Abstract] [Full Text] [Related]
28. [An epidemic of meningococcal meningitis in the region of Savanes in Togo in 1997: research and control strategies]. Aplogan A; Batchassi E; Yakoua Y; Croisier A; Aleki A; Schlumberger M; Molina S; Sidatt M; Kaninda AV Sante; 1997; 7(6):384-90. PubMed ID: 9503496 [TBL] [Abstract][Full Text] [Related]
29. [Tetravalent anti-meningococcal vaccine: serologic and clinical evaluation]. Vescia N; Mastroeni I; Pompa MG; Signorelli C; Fara GM Ann Ig; 1989; 1(6):1293-8. PubMed ID: 2484465 [TBL] [Abstract][Full Text] [Related]
30. Surveillance of vaccine breakthrough cases following MeNZB vaccination. McNicholas A; Galloway Y; Martin D; Sexton K; O'Hallahan J N Z Med J; 2008 Apr; 121(1272):38-46. PubMed ID: 18425153 [TBL] [Abstract][Full Text] [Related]
31. The strategy to control New Zealand's epidemic of group B meningococcal disease. O'Hallahan J; Lennon D; Oster P Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072 [TBL] [Abstract][Full Text] [Related]
32. An evaluation of the immunogenicity and safety of a new trivalent meningococcal polysaccharide vaccine. Chandramohan D; Hodgson A; Coleman P; Baiden R; Asante K; Awine E; Owusu-Agyei S; Boutriau D; Nelson CB; Greenwood B Vaccine; 2007 Sep; 25 Suppl 1():A83-91. PubMed ID: 17521782 [TBL] [Abstract][Full Text] [Related]
33. [Meningococcal disease in the Netherlands: media hype, but not an epidemic]. van Furth AM; Zaaijer HL Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1716-8. PubMed ID: 11572168 [TBL] [Abstract][Full Text] [Related]
35. [Meningococcal disease in Africa--epidemiology and prevention]. Norheim G; Rosenqvist E; Aavitsland P; Caugant DA Tidsskr Nor Laegeforen; 2000 Jun; 120(15):1735-9. PubMed ID: 10904659 [TBL] [Abstract][Full Text] [Related]
36. Challenges and progress in the development of a serogroup B meningococcal vaccine. Lewis S; Sadarangani M; Hoe JC; Pollard AJ Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263 [TBL] [Abstract][Full Text] [Related]